Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ULCC +3.9% (lowers guidance), JPM +2.7%, MS +2.7%, BLK +1.9%, BK +1.8%, WFC +1.6%
Other news:
- CERT +18.4% (FDA to phase out animal testing in certain therapies)
- RXRX +14% (FDA to phase out animal testing in certain therapies)
- TARA +6.7% (to present interim analysis from Phase 2 trial of TARA-002)
- VERV +6.6% (receives U.S. FDA fast track designation for VERVE-102)
- YRD +5.4% (receives regulatory approval for commercial use of Zhiyu Large Model)
- ARGX +5.1% (FDA approves VYVGART Hytrulo Prefilled Syringe for Self-Injection)
- MLM +2.2% (CFO James Nickolas to resign; guides Q1 revs in-line)
- CRL +2.1% (FDA to phase out animal testing in certain therapies; stock sold off late Thurs but recovering pre-mkt)
- HOG +1.9% (exploring $1+ bln sale of its financing arm, according to Bloomberg)
- TRGP +1.7% (increases dividend)
- LCID +1.6% (to acquire select assets previously belonging to Nikola)
- AGX +1.4% (increases share repurchase program to $150 mln)
- ADC +1.4% (increases dividend)
- QGEN +1.4% (announces software win)
- SMG +1.3% (transfers Hawthorne Collective to an independent strategic partner)
- AGNC +1.1% (announces Q1 data)
- CNH +1% (CFO to step down, names new CFO)